CORDIS
EU research results

CORDIS

English EN
Collaboration for innovation: Establishment of a pan-nematode drug development platform

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Objective

To target helminth elimination, a drug research and development (R&D) pipeline is needed to provide new chemotherapeutics that effectively eliminate or sterilize adult worms, thus bringing about the paradigm shift necessary to reach the 2030 SDG goals on health. Our consortium proposes to establish a R&D pipeline for anthelminthics targeting nematodes. The focus will be on soil-transmitted helminthiasis and onchocerciasis, since these infections are among the leading neglected tropical diseases. Ground breaking characteristics of the drugs developed within our project are that they will have a unique mechanism of action that, at best, will target multiple nematodes (pan-nematode) with an excellent safety profile, including no efficacy against non-targeted co-endemic species. We will benefit from collaborations with our industrial partners Bayer and Celgene providing preselected compounds to populate the early preclinical stages of the R&D pipeline. Compounds with the best profile will be progressed through preclinical studies. Corallopyronin A, a compound with proven efficacy against essential Wolbachia endosymbionts in filariae that has superiority to the gold standard doxycycline, excellent bioavailability and promising exploratory safety data will undergo state-of-the-art toxicity profiling to advance towards phase 1 trials. We will also evaluate oxfendazol and oxantel pamoate in clinical trials. They have already proven efficacious in animals or humans and will only require clinical trials according to current regulatory guidelines to be implemented. With this strategy, the consortium will ensure that a pipeline of drug candidates is available for treating onchocerciasis, especially should current candidates fail in upcoming clinical trials. Moreover, we will establish a much-needed drug R&D pipeline to treat soil-transmitted helminth infections for which there is currently neither a drug with good efficacy against all species nor any prospects on the horizon.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

Address

Socinstrasse 57
Ch-4002 Basel

Switzerland

Activity type

Research Organisations

EU Contribution

€ 3 385 143,75

Participants (7)

Sort alphabetically

Sort by EU Contribution

Expand all

DRUGS FOR NEGLECTED DISEASES INITIATIVE FONDATION DNDI

Switzerland

EU Contribution

€ 2 285 375

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 1 839 714,16

MUSEUM NATIONAL D'HISTOIRE NATURELLE

France

EU Contribution

€ 284 500

UNIVERSITY OF BUEA

Cameroon

EU Contribution

€ 98 156,26

IFAKARA HEALTH INSTITUTE TRUST

Tanzania

EU Contribution

€ 820 506,25

CELGENE MANAGEMENT SARL

Switzerland

BAYER ANIMAL HEALTH GMBH

Germany

Project information

Grant agreement ID: 815628

Status

Grant agreement signed

  • Start date

    1 September 2019

  • End date

    31 August 2024

Funded under:

H2020-EU.3.1.3.

Coordinated by:

SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

Switzerland